Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.

Article Details

Citation
Copy to clipboard

Mahoney CE, Mochizuki T, Scammell TE

Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.

Sleep. 2019 Dec 13. pii: 5674930. doi: 10.1093/sleep/zsz302.

PubMed ID
31830270 [ View in PubMed
]
Abstract

Orexin receptor antagonists are clinically useful for treating insomnia, but thorough blockade of orexin signaling could cause narcolepsy-like symptoms. Specifically, while sleepiness is a desirable effect, an orexin antagonist could also produce cataplexy, sudden episodes of muscle weakness often triggered by strong, positive emotions. In this study, we examined the effects of dual orexin receptor antagonists (DORA's), lemborexant (E2006) and almorexant, on sleep/wake behavior and cataplexy during the dark period in wild-type (WT) mice and prepro-orexin knockout (OXKO) mice. In WT mice, lemborexant at 10 and 30 mg/kg quickly induced NREM sleep in a dose-dependent fashion. In contrast, lemborexant did not alter sleep/wake behavior in OXKO mice. Under the baseline condition, cataplexy was rare in lemborexant-treated WT mice, but when mice were given chocolate as a rewarding stimulus, lemborexant dose-dependently increased cataplexy. Almorexant produced similar results. Collectively, these results demonstrate that DORA's potently increase NREM and REM sleep in mice via blockade of orexin signaling, and higher doses can cause cataplexy when co-administered with a likely rewarding stimulus.

DrugBank Data that Cites this Article

Drugs